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1Ofﬁce of Health Economics, London, UK; 2Sanoﬁ Pasteur MSD, Berkshire, UKA B S T R A C TObjective: To investigate the use of patient-reported outcomes (PROs)
in pediatric populations with vaccine-preventable infectious diseases
in high-income Western countries. Methods: Systematic review of
PRO use in populations younger than 18 years with any of 17
infectious diseases for which vaccines are available or in develop-
ment. The search was limited to studies performed in Europe, North
America, Australia, and New Zealand and published between January
1, 1990, and July 31, 2013. Searches were conducted in Scopus and
PsycINFO, and reference lists were manually searched. Results are
reported using the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses guidelines. Results: Of 6410 titles and abstracts
and 174 full-text articles reviewed, 17 full-text articles were included
for data extraction. The largest number of PRO studies was carried out
in patients with anogenital warts and rotavirus gastroenteritis. No
PRO studies were identiﬁed for nine conditions. A total of 24 PROee front matter Copyright & 2016, International S
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ndence to:Michael Herdman, Ofﬁce of Health Economeasures (12 generic and 12 disease-speciﬁc) were used in the studies
reviewed. Most of the instruments used were of high quality. Proxy
responses were occasionally obtained when self-report would have
been feasible. No validated disease-speciﬁc instruments for children
with any of the conditions studied were found. Conclusions: The
paucity of studies and PRO instruments to assess pediatric health
status in vaccine-preventable infectious diseases, and the lack of a
standardized approach to measurement, makes it difﬁcult to capture
the impact of disease and the beneﬁt of vaccination and could
potentially hinder decision making. Guidelines from relevant bodies
to steer research in this area would be useful.
Keywords: infectious diseases, literature review, patient-reported
outcomes, pediatric.
Copyright & 2016, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The assessment of patient-reported outcomes (PROs), such as
health-related quality of life (HRQOL), plays an increasingly
important part in evaluating the impact of disease and its treat-
ment. The accurate assessment of that impact requires the use of
appropriately developed and tested instruments suitable for use
in the population of interest. Although most of the PRO instru-
ments to assess constructs such as HRQOL have been developed
for use in adult populations, an increasing number have also
been developed for pediatric populations, here deﬁned as those
younger than 18 years [1,2]. This is important because the
concepts that are relevant to a construct such as HRQOL may
differ between adults and children; for example, issues such as
relationships with friends and peer group approval, home and
family life, and self-esteem are likely to be more relevant to
children [3,4]. Obtaining PRO data from pediatric populations alsoposes challenges that are not faced when dealing with adult
populations, such as the need to use appropriate age-related
vocabulary, comprehension of health concepts, and the possible
need to use proxy respondents, such as parents, in younger
children [5,6].
Likewise, it is fair to say that most of the instruments used to
measure HRQOL and similar constructs have been developed for
use in chronic diseases. For example, in the review by Solans
et al. [2], of the 64 disease-speciﬁc instruments identiﬁed for use
in children and adolescents, none was developed speciﬁcally for
use in infectious diseases. Even generic instruments, which are
theoretically suitable for use in any population, have not been
widely used in patients with infectious or acute disease. In a
review covering all populations and all types of quality-of-life
(QOL) measures, only 11 of 3921 reports identiﬁed by the authors
as referring to the development or use of QOL instruments
related to infectious conditions [7]. The situation may beociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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given the added difﬁculty of obtaining reliable data, especially
from younger children. However, the impact of infectious dis-
eases on constructs such as HRQOL can be severe [8].
If it is the case that the PRO impact of infectious diseases in
children is under-researched, then the impact of those diseases
and their treatment or prevention are likely to be less well
quantiﬁed than is the case for chronic illnesses [9], making it
difﬁcult to capture the full value of vaccination or other treat-
ments. To date, however, there has been no thorough published
review of the use of PRO instruments in children and adolescents
with vaccine-preventable infectious diseases, nor of the results
they have generated. The Patient-Reported Outcomes in Children
with Infectious Diseases (PROCHID) study was designed to address
this evidence gap by systematically reviewing studies that had
used PROs or that had elicited utility weights and/or used those
weights in modeling studies in children with any of the 17
infectious diseases listed in Appendix 1 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2015.10.001. The present
article reports our ﬁndings related to the use of PRO instruments.
The objectives of the present study were therefore to identify
studies reporting on the use or development of PRO instruments
in children with vaccine-preventable infectious diseases and to
provide an overview of those instruments in terms of their
quality and how they have been used in this population.Methods
Data Sources, Search Strategy, and Eligibility Criteria
This review was performed according to a predeﬁned protocol
and results are reported following the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses recommendations
[10]. In the ﬁrst stage of the review, we aimed to identify any
study published between January 1, 1990, and July 31, 2013, which
reported on the use of PRO instruments in pediatric populations
(deﬁned here as children and adolescents between the ages of 0
and 18 years) with any of the vaccine-preventable infectious
diseases listed in Appendix 1 in Supplemental Materials. We
searched for studies in the Scopus search engine, which com-
bines MEDLINE and Embase. The searches in Scopus were carried
out using terms related to PROs and to pediatric populations,
with searches being run for each of the diseases of interest. The
search strategy for diphtheria is provided as an example in
Appendix 2 in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2015.10.001. The searches were designed to
identify studies dealing with the development, validation, lin-
guistic adaptation, or application of PRO instruments in pediatric
populations (i.e., children and adolescents up to the age of 18
years) with any of the infectious diseases of interest. Additional
searches were performed to identify articles reporting on the use
of utilities in the populations of interest; the methods and resu-
lts of that part of the PROCHID study are reported elsewhere
(Herdman M, Cole A, Hoyle CK, et al., The sources and character-
istics of utility weights for economic evaluation of paediatric
vaccines: a systematic review. Value in Health. In Press).
The search focused on publications in English or Spanish,
which were the languages the study team was able to work in.
We restricted the search to Europe, North America, Australia, and
New Zealand to ensure feasibility and because those are regions
and countries in which PROs are widely used and can contribute
to decision making on the value of treatments. We were also
interested, in this context, in whether and how PROs have been
used to assess the impact of infectious diseases and their treat-
ment, particularly when those diseases have either been eradi-
cated or are very well controlled. We also searched the PsycINFOdatabase for additional material on conditions for which at
least one relevant publication had been identiﬁed in the Scopus
search. For further information on PRO instruments, we searched
the PROQOLID [11] and BiblioPRO [12] databases.
Study Selection
Two reviewers (M.H. and C.K.H.) independently screened the
titles and abstracts of all studies identiﬁed by the search algo-
rithms to determine whether they met selection criteria. The aim
was to include studies dealing with the application, development,
or validation of any type of PRO in all possible study designs,
including randomized controlled trials, observational studies,
validation studies, epidemiological studies and surveys, ques-
tionnaire development studies, or qualitative studies. When
deciding whether an instrument was a PRO or not, we used the
deﬁnition of a PRO as “any report of the status of a patient’s
health condition that comes directly from the patient, without
interpretation of the patient’s response by a clinician or anyone
else” [13]. Instruments, however, could be completed by the child/
adolescent or by parents or other proxies, as long as the child’s
health was being evaluated. Studies reporting self-ratings by
parents or other family members of their own health were
excluded. For studies meeting all selection criteria, we retrieved
full-text articles for further review. Reference lists of all full-text
articles retrieved were searched for further relevant studies.
Data Extraction
Data were extracted from retrieved full-text articles by one of two
reviewers (M.H. and C.K.H.) using a predesigned data extraction
form that included questions on the following: setting; study type
(questionnaire development, validation, adaptation, or applica-
tion, and type of application, e.g., clinical trial or observational
study); study objectives; characteristics of the study population,
including age groups; type of PRO instrument (generic or disease-
speciﬁc); administration (PROs completed by parents, children,
both, or other; mode of administration); whether there was any
assessment of child–parent agreement; summary of main results
including whether authors reported both statistical and clinical
signiﬁcance; and any study limitations reported by the authors
relating to the use of PROs. A second data extraction form was
used to collect information on the PRO instruments used in any
studies identiﬁed. Any doubts arising at any point during the data
extraction process were resolved by recourse to a third reviewer
(N.D.). As a check on the quality of data extraction, a sample of
each reviewer’s extracted data for a random 10% of the articles
included for each condition was cross-checked by the other
reviewer. If discrepancies were found, the two reviewers dis-
cussed the discrepancies to determine their cause and decide
what further actions were required.
Data Synthesis and Analysis
Data from the review were summarized initially in terms of the
key features of the studies included and then in terms of the
more speciﬁc PRO-related aspects on the basis of components of
the data extraction form described above. PRO instrument quality
was evaluated on the basis of availability of data and the
performance of the instruments in terms of content validity,
reliability, construct validity, and responsiveness. The evaluation
of PRO instrument quality was carried out by one reviewer (M.H.)
using the criteria included in the Evaluating Measures of Patient
Reported Outcomes (EMPRO) instrument evaluation system [14].
A summary of the most pertinent ﬁndings for each condition was
developed after a review and discussion of the results by the
study team. We did not perform a quantitative data synthesis
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summarize instrument use and characteristics.Results
The searches in electronic databases for studies using PROs or
utilities in pediatric populations in the vaccine-preventable
infectious diseases of interest yielded 6410 journal article
references. Of these, 6301 were excluded because of either
duplication or a failure to meet the inclusion criteria after title
and/or abstract review (Fig. 1). Full-text articles were then
retrieved and reviewed for 107 journal references (it was not
possible to obtain two of the articles identiﬁed). Hand searching
of reference lists led to the identiﬁcation of a further 69 journal
articles considered suitable for full-text review. In total, there-
fore, 176 full-text articles were reviewed. Of the full-text articles
reviewed, 86 did not meet the inclusion criteria. The remaining
90 articles were retained for data extraction. Of these, 17
referred to studies that had used PROs to assess concepts such
as HRQOL or similar constructs in the conditions and population
of interest. The remaining full-text articles focused on the
generation and use of utility weights and are dealt with in
another article (Herdman M, Cole A, Hoyle CK, et al., The sources
and characteristics of utility weights for economic evaluation of
paediatric vaccines: a systematic review. Value in Health. In
Press).
Of the 17 full-text articles on which data extraction was
performed (see Table 1), 4 dealt with anogenital warts [15–18], 3
with inﬂuenza [19–21], and 5 with the impact of meningitis,
though these are classiﬁed in Table 1 according to the causative
agents, which included Haemophilus inﬂuenzae type B [22], menin-
gococcal meningitis [23], bacterial meningitis in general [22,24],
and pneumococcal disease [25,26]. Of the studies dealing with
bacterial meningitis in general, one dealt with pneumococcal and
bacterial meningitis but excluded that caused by H. inﬂuenzaeStudies included in qualitative 
synthesis (n=17) 
Full text articles assessed for 
eligibility (n=176) 
Records screened 
(n=5772) 
Records identified from 
electronic databases 
(n=6410) 
Records after duplicates removed
(n=5772) 
Rec
se
Fig. 1 – PRISMA ﬂow diagram. PRISMA, Preferred Reporting Item
the articles excluded here dealt with the use of utilities in the p
article.type B [24] and the other dealt with bacterial meningitis caused
by any of the three pathogens mentioned [22]. In addition, we
found four studies in rotavirus [27–30] and one in patients with
varicella [31]. The ﬁve meningitis studies identiﬁed all dealt with
the impact of postmeningitis sequelae on QOL. No full-text
articles meeting inclusion criteria were found for diphtheria,
hepatitis B, measles, mumps, rubella, norovirus, pertussis, polio,
or tetanus.
Table 1 presents the number and key characteristics of the
studies included for the conditions in which PROs had been used
in the target age group. The number of studies performed in each
condition ranged from one in the case of varicella to four for
anogenital warts, pneumococcal disease, and rotavirus. Approx-
imately half the studies reviewed were performed before 2000,
mostly in Europe. Almost all the articles reported on the appli-
cation of PRO measures in observational studies. Only two [19,20]
reported on their use in clinical trials, and two [15,30] reported on
the development of a new instrument. Sample sizes ranged from
25 [30] to 2023 [29]. The age groups studied ranged from very
young (o2 years) in the case of rotavirus to teens in the case of
anogenital warts and inﬂuenza.
Table 2 presents the main characteristics of the studies as
they relate to PROs. The great majority of the articles reported on
the application of PROs rather than on development or valida-
tion. As described in more detail later, most of the studies used
well-developed, previously validated instruments, though the
measurement approach varied considerably, with approximately
half the studies using only one instrument and the rest using two
or more. A total of 27 instruments were applied or developed in
the studies reviewed, including variants of the same instrument
(e.g., Health Utilities Index [HUI] 2 and HUI3). Of these, 10 could be
considered disease- or condition-speciﬁc (CECA (Cuestionario
Especíﬁco para Condylomata Acuminata) for anogenital warts,
Index of Erectile Dysfunction for erectile dysfunction, the Persson
et al. scale, the Bettis et al. visual analogue scales for inﬂuenza,
Paediatric Asthma Quality of Life Questionnaire for pediatricFull text articles excluded, 
n=159*  
Records excluded 
(n=5596) 
 
ords identified from hand-
arching of reference lists 
(n=69) 
s for Systematic Reviews and Meta-Analyses. *A number of
opulations of interest. This topic is dealt with in another
Table 1 – Key features of the included studies.
Condition Author Year of
publication
Year(s) of
study
Location Study type Sample size Age, mean or
median (and range)
(y)
Anogenital warts Badia et al. [15] 2005 2003 Spain QD, QT 135 31.1
Conaglen et al. [16] 2001 1998–1999 New Zealand OSL 141 22 (16–71)
Jeynes et al. [17] 2009 NR England OSC 120 25.6 (16–65)
Persson et al. [18] 1993 1990–1991 Sweden OSC 140 23.3 (15–46)
Inﬂuenza Bettis et al. [19] 2006 1997–1999 NR CT 1642 (no data
available on
numbers o18 y)
34 (13–64)
Bueving et al. [20] 2004 1999–2001 The Netherlands CT 696 10.5 (6–18)
Hollmann et al. [21] 2013 2009–2010 Spain OSL 432 inpatients (64
aged 8–18 y)
43.4 (8–465)
563 outpatients (82
aged 8–18 y)
Haemophilus inﬂuenzae
type B
Sumpter et al. [22] 2011 NR Scotland OSC 100 10
Meningitis B/C Borg et al. [23] 2009 1999–2002 England Matched cohort 40 16–18
Koomen et al. [24] 2005 1999 The Netherlands OSC 182 9.7
Sumpter et al. [22] 2011 NR Scotland OSC 100 10
Pneumococcal disease Christie et al. [25] 2011 NR England Population-based
case–control study
Range from n ¼ 4 to
n ¼ 95 depending on
questionnaire and
respondent (child or
parent)
7.7 (3–20)
Koomen et al. [24] 2005 1999 The Netherlands OSC 182 9.7
Legood et al. [26] 2009 NR England Case–control study 69 9.9 (5.4–20)
Sumpter et al. [22] 2011 NR Scotland OSC 100 10
Rotavirus Diez Domingo et al. [27] 2012 NR Spain, Poland,
Italy
OSC 264 0–5
Hoffmann et al. [28] 2011 2008–2009 Denmark OSL 354 o5
Huppertz et al. [29] 2008 2005–2006 Germany OSC 2023 o2
Johnston et al. [30] 2013 2010, 2011 Canada QD 25 Parents of children
aged 3 mo to 5 y
Varicella McKenna and Hunt [31] 1994 NR NR (UK?) OS, OSL 69 parents, 46
families
Parents of children
aged 6 mo to 16 y
CT, clinical trial; NR, not reported; OSC, observational study, cross-sectional; OSL; observational study, longitudinal; QD, questionnaire development; QT, questionnaire translation.
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Table 2 – PRO-related study features.
Condition Author PRO No. of
PROs
Names Type Reporting Agreement Comments
Anogenital warts Badia et al. [15] D, V 1 CECA (disease-speciﬁc
questionnaire for genital warts)
DS NR NA Content validity not tested in
adolescent populations
Conaglen et al. [16] App 3 General Health Questionnaire
28-item version
G, DS SR NA Small sample size for patients
with HPV (n ¼ 28)
Index of Erectile Dysfunction
Brief Index of Sexual Function
Jeynes et al. [17] App 1 CECA DS SR NA Study designed to test the
effect of shame and low self-
esteem on QOL
Persson et al. [18] App 1 University of Goteborg Mood
Adjective Checklist
DS NR NA –
Inﬂuenza Bettis et al. [19] App 3 NR DS NR NA Authors used three separate
VAS scales to measure the
effect of oseltamivir on health,
sleep, and activities
Bueving et al. [20] App 1 PAQLQ DS NR NA PAQLQ used as the study
focused on the impact of
inﬂuenza vaccination on
asthmatic children
Hollmann et al. [21] App 2 EQ-5D G P NA Proxy responses used for
subjects aged 8–17 yEQ-5D-Y
Haemophilus
inﬂuenzae type B
Sumpter et al. [22] App 2 SDQ G SR, P NA Assumed PedsQL was self-
reported by children— not
explicitly stated
PedsQL
Meningitis B/C Borg et al. [23] App BDI G, DS SR NA –
SF-36
Chalder Fatigue Scale
Koomen et al. [24] App 2 Child Health Questionnaire
Parent Form
G P NA -
HUI2
Sumpter et al. [22] App 2 SDQPedsQL G SR, P NA Assumed PedsQL was self-
reported by children— not
explicitly stated
Pneumococcal
disease
Christie et al. [25] App 5 BDI (Z16 y) G SR, P NR Only included subjects with
pneumococcal meningitisMFQ parent report short form
(subjects aged 4–15 y)
MFQ self-report short form
(subjects aged 8–15 y)
SDQ (parent report for 3–16 y
and self-report for 11–16 y)
PedsQL (parental and self-
perception in Z5 y)
Functional Disability Index
continued on next page
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Table 2 – continued
Condition Author PRO No. of
PROs
Names Type Reporting Agreement Comments
Koomen et al. [24] App 2 Child Health Questionnaire –
Parent Form 50, HUI2
G P NA -
Legood et al. [26] App 1* HUI3 G SR, P NR Self-report in children aged
Z11 y; parent report in
children aged 5–10 y
Sumpter et al. [22] App 2 SDQ G SR, P NA Assumed PedsQL was self-
reported by children— not
explicitly stated
PedsQL
Rotavirus Diez Domingo et al.
[27]
D,
App
1 No name given. DS P NA Use of measures, e.g., PAMODI,
which have not undergone
formal psychometric validation
Questionnaire with 44 items in
ﬁve scales
Hoffmann et al. [28] App 1 EQ-5D G P NA Authors comment that no
satisfactory generic HRQOL
instrument developed for
children o5 y
Huppertz et al. [29] App 1 PAMODI DS P NA PAMODI instrument arguably
does not measure QOL, as
claimed by the authors
Johnston et al. [30] D 2 Child Acute Gastroenteritis
Questionnaire
DS NA NA Authors comment that the
development of QOL
instruments for acute
conditions is a new area of
research
Parent Acute Gastroenteritis
Questionnaire
Varicella McKenna and Hunt
[31]
D, V 1 The Family Disruption Scale DS P NA The ﬁnal instrument contained
25 items that were not speciﬁc
to chickenpox, so authors
suggest that it can be used
when studying any minor
childhood illness
App, application; B, both; BDI, Beck Depression Inventory; D, development; CECA, Cuestionario Especíﬁco para Condylomata Acuminata (Spanish acronym for the Speciﬁc Questionnaire for
Condylomata Acuminata); DS, disease-speciﬁc; EQ-5D, EuroQol ﬁve-dimensional questionnaire; EQ-5D-Y, EuroQol ﬁve-dimensional questionnaire – Youth version; G, generic; HPV, human
papillomavirus; HUI2, Health Utilties Index mark 2; HUI3, Health Utilities Index mark 3; HRQOL, health-related quality of life; MFQ, Moods and Feelings Questionnaire; NA, not applicable; NR,
not reported; P, proxy; PAMODI, Parental Appraisal of the Morbidity of Diarrhoea in Infants; PAQLQ, Paediatric Asthma Quality of Life Questionnaire; PedsQL, Pediatric Quality of Life; SF-36,
short form 36 health survey; QOL, quality of life; SDQ, Strengths and Difﬁculties Questionnaire; SR, self-report by child/adolescent; V, validation; VAS, visual analogue scale.
* The Legood and Christie articles report on different aspects of the same study. The number of instruments refers to the number reported in each article, not the overall number in the study.
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V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 1 0 9 – 1 1 9 115asthma, the Beck Depression Inventory for depression, the Diez
Domingo et al. scale, the Parental Appraisal of the Morbidity of
Diarrhoea in Infants [PAMODI] questionnaire for diarrhea, and
Child Acute Gastroenteritis Questionnaire and Parent Acute
Gastroenteritis Questionnaire for acute gastroenteritis). Of all
the instruments identiﬁed, only one disease-speciﬁc instrument
(the Child Acute Gastroenteritis Questionnaire/Parent Acute Gas-
troenteritis Questionnaire for acute gastroenteritis) speciﬁcally
explored domains that were relevant to children and parents
separately. Of the other instruments speciﬁc to
the conditions of interest, some were designed to elicit res-
ponses from parents [27,29], whereas others appear to have
been primarily designed for adults and then applied in popula-
tions younger than 18 years [16,17,19]. At least one of the
scales could be described as being an ad hoc, study-speciﬁc
measure [27].
Of the generic instruments identiﬁed, six were designed to be
used with pediatric populations. These were the Child Health
Questionnaire Parent Form 50, which is designed to capture
parents’ assessments of their children’s overall HRQOL across
14 physical and psychosocial domains [32]; the EuroQol ﬁve-
dimensional questionnaire – Youth version, which is designed
primarily for use in children aged between 7 and 12 years [33]; the
Functional Disability Index, which is designed to assess the
impact of physical health status on the ability to perform 15
daily activities [34]; the HUI, a preference-based measure of seven
or eight health attributes (depending on the version) for use in
respondents aged 5 years and above [35]; the Pediatric Quality of
Life, an instrument to assess HRQOL in four domains for use in
populations aged 2 years and above [36]; and the Strengths and
Difﬁculties Questionnaire, which is a brief screening question-
naire used to identify behavioral and emotional problems in
children and adolescents [37].
In terms of questionnaire administration, most of the studies
used parent report or a mixed approach (i.e., parent reporting for
younger children and self-report in older children and adoles-
cents). In some cases (e.g., rotavirus), the use of parent reports
was unavoidable because of the very young age of the target
group. In other cases [24,28], at least some of the pediatric age
subjects could arguably have completed the PROs themselves. In
a small number of cases, it was not reported [18,19] or not clear
[20] whether the instruments were completed by the child/
adolescent or by parents. None of the articles reported testing
the agreement between child and parent ratings; in most of the
cases, this was not possible because only one type of report was
obtained.
Table 3 presents the results of appraising the instruments
used in the studies. Most of the instruments used were well-
tested measures that have shown satisfactory psychometric
properties. Three exceptions were the Goteborg Mood Adjective
Checklist together with the other ad hoc questionnaire used in
the Persson et al. study for anogenital warts and the PAMODI
questionnaire used for infant and toddler diarrhea [29]. The ﬁrst
two of these, however, were used in a study carried out more
than 20 years ago, before the use of PROs was well established.
The PAMODI questionnaire was also arguably an ad hoc
questionnaire used in one speciﬁc study; we were unable to ﬁnd
any information relating to the development procedure or its
psychometric properties. In the case of the Child Acute Gastro-
enteritis Questionnaire and the Parent Acute Gastroenteritis
Questionnaire, a lack of information relating to instrument
properties is to be expected, given that these are relatively new
measures.
Table 4 summarizes the key ﬁndings for each condition
studied. Clearly, one of the most relevant ﬁndings was the sheer
absence of studies exploring and measuring PRO issues that
might be relevant to children and the parents of children withthe conditions of interest studied in this article. In 9 of the 17
conditions studied, no reports were found of PRO studies of any
sort. Another key ﬁnding common to almost all the conditions
studied was the lack of disease-speciﬁc instruments for pediatric
populations with the disease. A disease-speciﬁc instrument
speciﬁcally designed to address issues relevant to pediatric
populations was available only for rotavirus [30].Discussion
As far as we are aware, this is the ﬁrst systematic review of PRO
studies carried out in a wide range of vaccine-preventable
infectious diseases. Such reviews are important because in
addition to summarizing the research to date, they show where
gaps exist and thus help orient future research. In the present
case, there have been so few studies in pediatric age populations
with the infectious diseases studied here that there is substantial
scope for further research.
No doubt one of the reasons that we identiﬁed so few studies
is that several of the diseases have been virtually eradicated from
the countries that were the objective of the present review.
Nevertheless, we were particularly interested in those countries
because PRO research is well established there and can contrib-
ute to decision making and because we were interested in how it
might be applied in a situation in which the low prevalence of
speciﬁc diseases can make it difﬁcult to assess their impact.
However, not taking the PRO perspective into account when
assessing the impact of prevention of diseases such as diphthe-
ria, tetanus, or polio could lead to the beneﬁts associated with
their prevention being underestimated. At the same time, PROs
could also have a role to play in evaluating any possible harm
associated with a given vaccine, to provide a fuller risk-beneﬁt
assessment. Guidance on how to deal with these issues when
evaluating preventive treatments in countries where the preva-
lence of many serious infectious diseases has been reduced by
vaccination would be useful. Another reason for the small
number of studies identiﬁed might be that the measurement of
HRQOL during childhood would not provide useful data in some
cases. For instance, the more serious effects of hepatitis B
generally occur later in life and its impact on the health status
of pediatric age populations is likely to be minimal. In this case,
the negative impact of the disease and the consequent beneﬁts of
prevention would likely be better explored by comparing QOL
results in samples of adults with and without the disease.
Nevertheless, many of the other conditions studied here do
have a substantial impact on HRQOL and other PRO concepts
during childhood and/or adolescence. This is the case with the
diseases for which some research has been done (anogenital
warts, inﬂuenza, meningitis, rotavirus, varicella), but is also likely
to be true for diseases such as pertussis, measles, or mumps, for
which we were unable to locate any PRO studies to date. In these
cases, the relatively low prevalence of the disease coupled with
the usually short-term nature of the symptoms may lead to
practical difﬁculties with collecting data and account for the lack
of studies to some extent.
Even among the diseases on which some research has been
performed in pediatric age populations, only a relatively small
number of studies have been performed. For example, in patients
with varicella, we found only one PRO-related study, and that
was to develop a questionnaire to assess its impact on family life
rather than on the child’s health status [31]. As the development
of this questionnaire suggests, many of the diseases studied here
can have a signiﬁcant effect on carers’ QOL, and not just on the
person directly affected, but this was not a focus of the present
review. Nevertheless, it is an aspect to be taken into account
when evaluating the impact of this type of illness.
Table 3 – Assessment of instrument quality for PRO measures identiﬁed in the PROCHID review.
Instrument Content
validity
Reliability Validity Responsiveness Interpretation
Internal
consistency
Test-
retest
Known
groups
Convergent-
divergent
Criterion
Generic instruments
CHQ-PF50 ✓ ✓ ✓ ✓ ✓ X ✓ *
EQ-5D ✓ ✓ ✓ ✓ ✓ NA ✓ *
EQ-5D-Y ✓ X ✓ ✓ ✓ NA ✓ †
Family Disruption Scale ✓ ✓ X ✓ X NA ✓ †
Functional Disability Inventory ✓ ✓ ✓ ✓ ✓ NA ✓ †
GHQ-28 ✓ ✓ ✓ ✓ ✓ ✓ ✓ *
Goteburg Mood Adjective
Checklist
X X ? ? X NA X †
HUI ✓ ✓ ✓ ✓ ✓ NA ✓ *
Moods and Feelings
Questionnaire
✓ ✓ ? ✓ ✓ ✓ ✓ 0
PedsQL ✓ ✓ ✓ ✓ ✓ NA ✓ †
SDQ ✓ ✓ ✓ ✓ ✓ NA ✓ *
SF-36 ✓ ✓ ✓ ✓ ✓ NA ✓ *
Disease-speciﬁc instruments
BDI ✓ ✓ ✓ ✓ ✓ ✓ ✓ *
BISF ✓ ✓ ? ✓ ✓ NA X X
CAG-SAS ✓ X X X X NA X X
CECA ✓ ✓ ✓ ✓ ✓ ✓ ✓ †
IIEF ✓ ✓ ✓ ✓ ✓ NA ✓ *
PAMODI X X X X X X X X
PAG-SAS ✓ X X X X NA X X
PAQLQ ✓ ✓ ✓ ✓ ✓ NA ✓ †
Persson questionnaire for AGW X X X X X X X X
Notes. ✓, tested and acceptable or good; X, no information available or tested and unsatisfactory; ?, doubts about acceptability; 0, no or very scarce information. The column on “Interpretation”
refers to the availability of information such as the minimal important difference, between-group effect sizes, and/or population reference data, which facilitates interpretation of scale scores.
AGW, anogenital wart; BDI, Beck Depression Inventory; BISF, Brief Index of Sexual Function; CAG-SAS, Child Acute Gastroenteritis Questionnaire; CECA, Spanish acronym for the Speciﬁc
Questionnaire for Condylomata Acuminata; CHQ-PF50, Child Health Questionnaire – Parent Form 50; EQ-5D, EuroQol ﬁve- dimensional questionnaire; EQ-5D-Y, EuroQol ﬁve-dimensional
questionnaire – Youth version; GHQ-28, General Health Questionnaire, 28-item version; HUI, Health Utilities Index; IIEF, Index of Erectile Dysfunction; NA, not applicable; PAG-SAS, Parent
Acute Gastroenteritis Questionnaire; PAMODI, Parental Appraisal of the Morbidity of Diarrhoea in Infants; PAQLQ, Paediatric Asthma Quality of Life Questionnaire; PedsQOL, Pediatric Quality of
Life; PROCHID, Patient-Reported Outcomes in Children with Infectious Diseases; SDQ, Strengths and Difﬁculties Questionnaire; SF-36, short form 36 health survey.
* Considerable information available.
† Some information.
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Table 4 – Key ﬁndings for each of the conditions studied.
Condition Key ﬁndings and comments
AGWs ▪ Few studies examined the impact of AGWs on PROs, and none speciﬁcally in individuals younger than 18 y.
▪ Only a small number of subjects younger than 18 y were included in the studies that had examined the effect of
AGWs on PROs.
▪ No research performed to date to explore issues that are important to younger (o18 y) individuals and whether
these differ compared with adult populations.
▪ No explicit testing of validity of available disease-speciﬁc instruments in patients younger than 18 y.
Diphtheria ▪ No PRO studies identiﬁed in pediatric populations with this condition.
HiB ▪ Only one PRO study identiﬁed in a pediatric population that had suffered bacterial meningitis.
▪ Evidence for HiB meningitis is limited because 5% of the study participants were identiﬁed as having HiB as the
causal agent of their condition.
▪ Study focused on QOL associated with sequelae.
Hepatitis B virus ▪ No PRO studies identiﬁed in pediatric populations with this condition.
Inﬂuenza ▪ Very few PRO studies in pediatric populations.
▪ Lack of disease-speciﬁc instruments to assess inﬂuenza impact in pediatric populations.
▪ Proxy reports sometimes used when self-report would have been possible.
Measles ▪ No PRO studies identiﬁed in pediatric populations with this condition.
Mumps ▪ No PRO studies identiﬁed in pediatric populations with this condition.
Rubella ▪ No PRO studies identiﬁed in pediatric populations with this condition.
Meningococcal
meningitis B or C
▪ Three articles identiﬁed, two of which report on pediatric bacterial meningitis in general (including that caused
by Neisseria meningitidis).
▪ Study focusing speciﬁcally on meningococcal meningitis was conducted in late adolescents.
▪ Studies focused on QOL associated with postmeningitis sequelae.
Norovirus ▪ No PRO studies identiﬁed in pediatric populations with this condition.
Pertussis ▪ No PRO studies identiﬁed in pediatric populations with this condition.
Pneumococcal disease ▪ Four articles identiﬁed, two of which report on pediatric bacterial meningitis in general (including that caused
by Streptococcus pneumoniae) and two of which report speciﬁcally on pneumococcal meningitis.
▪ Pneumococcal meningitis was a minority causative agent in the general bacterial meningitis studies.
▪ Studies focused on QOL associated with postmeningitis sequelae.
Polio ▪ No PRO studies identiﬁed in pediatric populations with this condition.
Rotavirus ▪ Studies performed to date have focused on assessing the impact of the child’s condition on parents or on family
life, rather than the impact on the child.
▪ Efforts have begun to be made to develop instruments to measure the effect of gastroenteritis on the child’s
health status, via proxy reporting, with at least one disease-speciﬁc instrument available, though as yet
unvalidated.
▪ Weaknesses of the studies performed to date include the fact that in one case (Huppertz et al. [29]), the
questionnaire was administered between 1 and 6 mo after the diarrheal episode.
▪ In the same study, the authors used an ad hoc, untested instrument to measure QOL.
Tetanus ▪ No PRO studies identiﬁed in pediatric populations with this condition.
Varicella ▪ Only one study identiﬁed.
▪ Study reported on the development and validation of a PRO-type questionnaire to measure family disruption
for use in chickenpox and other minor illnesses.
▪ No other studies were identiﬁed in which this questionnaire or other PRO instruments had been used to assess
the impact of varicella on children or their families.
AGWs, anogenital warts; HiB, Haemophilus inﬂuenzae type B; PRO, patient-reported outcome; QOL, quality of life.
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to assessing PROs, from the use of multiple questionnaires to the
use of only one, use of proxy responses in some studies and self-
report in others, and substantial differences in sample size.
Obviously, in diseases such as rotavirus, which affects very young
children, it is necessary to rely on parent report due to the
difﬁculties associated with obtaining self-reports of health status
directly from children. In other conditions, such as inﬂuenza,
proxy reports were used when it may have been possible to
obtain self-reports from children [28].
Another ﬁnding was that questionnaires designed for adults
were occasionally used in children and adolescents. For example,
Hoffmann et al. [28] used the EuroQol ﬁve-dimensional question-
naire to assess HRQOL in children younger than 5 years, an agegroup in which the instrument may not be appropriate and in
which it has not been tested. Likewise, the CECA questionnaire
appears to have been primarily developed in and for adult
populations, but was also applied in older teenagers [17]. It is
not clear that issues that are important to younger patients
would be included in the questionnaire; in that sense, it would
be useful to explore the content validity of the instrument in
focus groups or interviews with younger individuals affected by
anogenital warts. In other studies [29], the use of unvalidated
instruments is also of concern.
The use of potentially inappropriate questionnaires might be
due in part to the lack of instruments designed speciﬁcally for use
in pediatric populations with these diseases. We identiﬁed only
one instrument [30] that was developed speciﬁcally for use in one
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of HRQOL can be useful in initial explorations of the impact of a
condition, or to compare the effect of different conditions on
HRQOL, disease-speciﬁc measures generally provide a more
relevant and precise means of assessing the impact of a partic-
ular condition on health status [38].
The lack of disease-speciﬁc instruments for use in these
populations and the scarcity of studies make it difﬁcult to
accurately reﬂect the impact of the diseases studied and to
capture the beneﬁts of prevention or treatment. A case in point
is that of meningitis B. In recent decisions by the Joint Committee
on Vaccination and Immunisation [39], the committee originally
found a new vaccine for meningitis B (Bexsero) to be not cost-
effective, though the decision was later reversed. One of the key
elements in reversing the decision was the use of quality-
adjusted life-year adjustment factor, which was implemented
because of a concern that QOL decrements had not been fully
captured. Greater availability of information on the QOL impact
of the disease would likely have improved estimates of QOL
losses and increased conﬁdence in the conclusions stemming
from cost-effectiveness modeling.
Health economics and health outcomes are fairly new ﬁelds,
and where a demonstration of cost-effectiveness is mandatory
this is a relatively new requirement. Vaccines could be said to be
victims of their own success: in some cases, routine vaccination
programs have been in place for decades and have thus elimi-
nated previously endemic diseases from the population. There is
little incentive to develop and use PROs for diseases that are so
well controlled, and the seriousness of these diseases and their
sequelae no longer features in the public mind. At the same time,
it is important to acknowledge the difﬁculties and challenges
involved in getting accurate pediatric QOL data [6,40]. This, in
turn, necessitates clear, transparent, and open decision-making
processes, so that any potential problems or weaknesses can be
discussed and addressed.
The main limitation of the present study is that the search
was restricted to high-income Western countries. As noted, this
was not only to ensure the feasibility of the review but also
because we were interested in how PRO research is carried out in
infectious diseases in countries where PRO measures are increas-
ingly widely used and relevant to decision making but in which,
paradoxically, the availability of effective vaccines can make it
difﬁcult to assess their impact in terms of PROs. Because the
review was restricted to this particular set of countries and
regions, the results may not be generalizable to other areas in
which the situation in terms of PRO research, and disease
patterns and prevalence, may be different. Future research in
this area could extend the current review to investigate PRO use
in these and other infectious diseases in other parts of the world,
including developing countries.
A second potential limitation of this study is that the literature
searches were performed only in Scopus and PsycINFO. We focused
particularly on Scopus because it is a very broad database that is
also versatile when performing the sort of complex searches used
here. We did not include other databases such as the Cochrane
Library or search the gray literature because we considered that the
Scopus and PsycINFO searches coupled with manual searching of
reference lists would identify the vast majority of relevant publica-
tions and any beneﬁts from searching additional databases would
be marginal. Nevertheless, future reviews could consider searches
in additional databases if time and resources allow.
A third limitation is that assessment of instrument quality
was performed by only one reviewer, though one with consid-
erable experience in this type of assessment. Nevertheless, by
their nature, such assessments are somewhat subjective and the
aim of this study was not to provide a detailed, in-depth assess-
ment of instrument quality but to give an overview of thepsychometric properties of the instruments identiﬁed and the
information available in that regard.
In conclusion, the paucity of studies using PROs to assess
pediatric health status in vaccine-preventable infectious dis-
eases, and the lack of disease-speciﬁc instruments for this
population, makes it difﬁcult to fully assess the impact of those
conditions or the beneﬁts associated with prevention and treat-
ment. This will hopefully be rectiﬁed as PRO research becomes
increasingly integral to assessing the value of health care inter-
ventions. By highlighting some of the difﬁculties involved in
research in this area, as well as the need for guidance on how
such research should be carried out, we hope this review will
provide a useful starting point for thinking about how best to
move ahead in this challenging ﬁeld.Acknowledgments
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